Skip to main content

Day: July 28, 2025

Mandalay Shareholders Overwhelmingly Approve Transaction with Alkane Resources

TORONTO, July 28, 2025 (GLOBE NEWSWIRE) — Mandalay Resources Corporation (“Mandalay” or the “Company“) (TSX: MND, OTCQB: MNDJF) is pleased to announce that Mandalay shareholders (the “Mandalay Shareholders”) have overwhelmingly approved a special resolution (the “Arrangement Resolution”) authorizing an arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”) pursuant to which Alkane Resources Limited (“Alkane”) (ASX: ALK, OTC: ALKEF) will indirectly acquire all of the issued and outstanding common shares of Mandalay (the “Mandalay Shares”) at a special meeting (the “Meeting”) of Mandalay Shareholders held earlier today on July 28, 2025. The Arrangement Resolution required the approval of at least two-thirds of the votes cast at the Meeting in person or by proxy by Mandalay Shareholders....

Continue reading

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placement agent fees and other offering expenses. The Series A-3 Preferred Stock is initially convertible into an aggregate of...

Continue reading

Can-Fite Announces Up To $15.0 Million Public Offering

$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced the pricing of a public offering with a single institutional investor of 8,333,333 of the Company’s American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 16,666,666 ADSs at a combined public offering price of $0.60 per ADS (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term...

Continue reading

Vicat – H1 2025 Results

Stable sales, up +0.2% like-for-like1 Unfavorable currency effects over the period EBITDA down -2.0% and consolidated net income up +6.3% like-for-like Solid cash flow generation and a €190 million reduction in net debt over 1 year 2025 EBITDA guidance adjusted to reflect currency effects: growth of +2% to +5% like-for-like(€ million)   First-half2025   First-half 2024 Changereported Change lfl*Consolidated sales 1,885 1,937 -2.7% +0.2%EBITDA   331   353 -6.3% -2.0%Margin (%)   17.5%   18.2% -0.7 pts  Recurring EBIT   169   188 -10.0% -4.4%Margin (%)   9.0%   9.7% -0.7 pts  Consolidated net income   116   115 +1.1% +6.3%Margin (%)   6.1%   5.9% +0.2 pts  Net income, Group share   102   104 -1.7% +3.1%Margin (%)   5.4%   5.3% +0.1 pts  Free cash flow   44   -23 ns  *like-for-like, i.e. at constant...

Continue reading

EssilorLuxottica: Q2/H1 2025 Results – Sound revenue growth at 7.3% in Q2 and H1, AI glasses speeding up further

Sound revenue growth at 7.3% in Q2 and H1 AI glasses speeding up furtherGroup’s revenue growing 7.3% in both Q2 and H1 (constant exchange rates1) North America accelerating in PS, DTC keeping a solid growth pace EMEA confirming the strong performance of PS and DTC, as the best region for the Group AI glasses Ray-Ban Meta up more than 200% in sales in H1 AI glasses Oakley Meta on the blocks, successful launch of the 50th anniversary edition Nuance Audio already rolled out in 10k doors across North America and Europe Adjusted2 operating margin stable at 18.3% in H1 (constant exchange rates1) Sound free cash flow5 generation at Euro 951 million Acquisition of Optegra clinics marking a further step into the new MedTech journeyParis, France (July 28, 2025 – 6:00 pm) – The Board of Directors of EssilorLuxottica met on July 28, 2025...

Continue reading

THEON presents its H1 2025 Trading Update

Facility THEON in KoropiFacility THEON in KoropiPRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS)28 July 2025 – Theon International Plc (THEON) (AMS: THEON) is today providing its H1 2025 Trading Update ahead of publishing its H1 2025 Report on 2 September 2025. H1 2025 performance was characterised by robust order intake, achievement of financial targets and solid progress in THEON’s growth strategy. Financial Summary(Amounts in €) H1 2025 H1 2024 ChangeOrder intake 167.9 m 77.0 m +118.1%Revenue 183.7 m 152.4 m +20.6%Adjusted EBIT1 47.4 m (45.9 m) 38.1 m (36.9 m) +24.4%Adjusted EBIT margin1 25.8% (25.0%) 25.0% (24.2%) +0.8 p.p.Earnings per share 0.48 0.41 +17.1%Capex 6.7 m 5.1 m +31.4%       (Amounts in €) Jun 2025 Mar 2025 ChangeSoft backlog 622.2 m 668.6 m -6.9%Net working capital 165.4...

Continue reading

Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today welcomes the White House’s release of “Winning the Race: America’s AI Action Plan”, issued July 23, 2025. The Company applauds the federal government’s emphasis on establishing domain-specific standards, regulatory sandboxes (aka AI Centers of Excellence), and stakeholder convenings led by The National Institute of Standards and Technology to build trust, governance, and productivity in healthcare AI. Aligned with AI Action Plan healthcare priorities, Tevogen.AI has recently developed the alpha version of PredicTcell™, a proprietary machine learning model built in collaboration with Microsoft (Nasdaq: MSFT) and Databricks. This model cuts weeks off target analysis in immunotherapy research, potentially...

Continue reading

Rexel’s First Half 2025 Financial Report   Made Available

REXEL’S FIRST HALF 2025 FINANCIAL REPORT   MADE AVAILABLE Rexel’s first-half 2025 financial report was filed on July 30, 2025 with the French Autorité des marches financiers (AMF). It is also made available on Rexel’s corporate website (https://www.rexel.com/en) in the “Investors –Regulated Information” section. ABOUT REXEL GROUP Rexel, worldwide expert in the multichannel professional distribution of products and services for the energy world, addresses three main markets: residential, non-residential, and industrial. The Group supports its residential, non-residential, and industrial customers by providing a tailored and scalable range of products and services in energy management for construction, renovation, production, and maintenance. Rexel operates through a network of more than 1,950 branches in 17 countries, with more than 27,000...

Continue reading

UES Expands into Indiana with Acquisition of GME Testing

Strategic move broadens the engineering firm’s Midwest footprint and drilling capabilities ORLANDO, Fla., July 28, 2025 (GLOBE NEWSWIRE) — UES, a national leader in geotechnical engineering, environmental consulting, materials testing and inspection services, has acquired GME Testing in Ft. Wayne, IN, expanding the firm’s Midwest region with the addition of its first Indiana-based firm. Established in 1999, GME Testing provides clients with geotechnical engineering, construction materials testing, and all foundation-related inspections and testing. The firm, comprised of 23 talented staff, also owns and operates their own fleet of drill rigs, further expanding UES’ drilling capabilities in the Midwest region. Among many other recent projects for hospitals, schools, and businesses, GME Testing’s recent notable projects include Trine...

Continue reading

Rexel: Q2 sales & H1 2025 results

 Q2 sales & H1 2025 resultsAcceleration of same day sales, fueled by North-America volume and priceResilient profitability, thanks to acceleration of self-help actionsFull-year guidance confirmed→ H1 25 sales of €9,775.3m up +1.6% on a same-day basis, showing a positive momentumAcceleration in Q2 25, up +1.8%, mainly driven by improving volume in North AmericaEuropean environment still challengingQ2 25 non-cable selling prices up +0.9%, with first positive impact from US tariffsDigital sales at 33.6% of sales in Q2 25, up +196bps, laying groundwork for future productivity gains→ Resilient H1 25 current adjusted EBITA margin of 5.8%, leveraging additional cost initiatives, with a (2.2)% FTE reduction in H1 25 when volume contributed to +0.4% to same-day sales growth → H1 25 operating income of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.